Anupam Rasayan to Acquire 43.30% Stake in Bliss GVS Pharma for ₹1,369 Crore
Anupam Rasayan India Limited will acquire 43.30% of Bliss GVS Pharma for ₹1,369.51 crore. The deal involves 4,58,03,024 shares at ₹299 each. This transaction will lead to a change in control and trigger an open offer for 26% of equity.
A change in control of the company due to a substantial acquisition of shares will significantly impact its strategic direction, management, and future operations.
The acquisition of a significant stake by a new entity and the potential for a change in control are generally viewed positively by the market, indicating growth and strategic shifts.
Bliss GVS Pharma Limited announced that its Board of Directors has taken note of a Public Announcement regarding the execution of a Share Purchase Agreement (SPA) dated May 23, 2026. The SPA was entered into between certain existing shareholders of Bliss GVS Pharma (the "Sellers") and Anupam Rasayan India Limited (the "Purchaser").
Under the SPA, the Purchaser has agreed to acquire 4,58,03,024 equity shares, representing 43.30% of the Company's paid-up equity share capital, from the Sellers. The Sellers include promoter and promoter group shareholders (Mr. Narsimha Shibroor Kamath, Dr. Vibha Gagan Sharma, Ms. Shruti Vishal Rao) and public/non-promoter shareholders (Mr. Gautam Rasiklal Ashra, Mr. Arjun Gautam Ashra, and M/s. Gulbarga Trading and Investment Private Limited).
The total consideration for this transaction is ₹1,369.51 crore (₹13,69,51,04,176), with each equity share valued at ₹299. The SPA also includes provisions for the Purchaser's option to acquire additional shares, referred to as "Balance Shares" and "Option Shares," under specific conditions and pricing mechanisms, potentially increasing the stake up to 4.90% more.
This transaction is expected to result in a change of shareholding and control of Bliss GVS Pharma, subject to the fulfillment of conditions precedent and receipt of applicable statutory and regulatory approvals. The execution of the SPA triggers the requirement for Anupam Rasayan India Limited to make an open offer to the public shareholders of Bliss GVS Pharma for up to 26% of the total paid-up equity share capital, in accordance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The Board of Directors meeting where this was noted commenced at 09:15 PM and concluded at 09:51 PM on May 23, 2026.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.